Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2652 Target Snapshot

cGMP-dependent 3',5'-cyclic phosphodiesterase · SINGLE PROTEIN · Homo sapiens

3,368Compounds
318Assays
5Approved Drugs
4,376.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O00408. Use UniProt O00408 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O00408 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-dependent 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL2652, mapped to UniProt O00408. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cGMP-dependent 3',5'-cyclic phosphodiesterase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2652
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O00408
cGMP-dependent 3',5'-cyclic phosphodiesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cGMP-dependent 3',5'-cyclic phosphodiesterase is the right protein anchor across sources, using UniProt O00408 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcGMP-dependent 3',5'-cyclic phosphodiesterase
UniProt AccessionO00408
Component TypeProtein
Sequence Length941 aa

cGMP-dependent 3',5'-cyclic phosphodiesterase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as cGMP-dependent 3',5'-cyclic phosphodiesterase, mapped to UniProt O00408. Sequence length is 941 aa.

Mapped IDO00408
Review namecGMP-dependent 3',5'-cyclic phosphodiesterase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase III
2
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC502,961.0
KI1,415.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5827044 10.8 Ki 0.016 Preclinical
CHEMBL5773913 10.77 Ki 0.017 Preclinical
CHEMBL6019094 10.7 Ki 0.02 Preclinical
CHEMBL5867733 10.66 Ki 0.022 Preclinical
CHEMBL6027642 10.62 Ki 0.024 Preclinical
CHEMBL370962 10.52 IC50 0.03 Preclinical
CHEMBL5948981 10.52 Ki 0.03 Preclinical
CHEMBL6040588 10.52 Ki 0.03 Preclinical
CHEMBL5847109 10.52 Ki 0.03 Preclinical
CHEMBL6032923 10.42 Ki 0.038 Preclinical
Distribution

pChEMBL Value Distribution

293
5.0
115
5.5
462
6.0
400
6.5
542
7.0
516
7.5
603
8.0
404
8.5
195
9.0
83
9.5
pChEMBL
Assay Landscape

Assay Landscape

318
Total Assays
2,789
Tested Compounds
3
Assay Types
Binding — 304 assays, 2,789 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 210 1,035 6.7
cell-based format 52 577 7.3
assay format 39 1,160 8.0
tissue-based format 3 17 4.6
Functional — 7 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 7 11 4.9
ADME — 7 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 4 11 5.5
cell-based format 3 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine